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Abstract
The 3 end of hepatitis E virus (HEV) contains cis-acting regulatory element, which plays an important role in viral replication. To
develop specific replication inhibitor at the molecular level, mono- and di-hammerhead ribozymes (Rz) were designed and synthesized
against the conserved 3 end sequences of HEV, which cleave at nucleotide positions 7125 and 7112/7125, respectively. Di-hammerhead
ribozyme with two catalytic motifs in tandem was designed to cleave simultaneously at two sites spaced 13 nucleotides apart, which
increases the overall cleavage efficiency and prevents the development of escape mutants. Specific cleavage products were obtained with
both the ribozymes in vitro at physiological conditions. The inactive control ribozymes showed no cleavage. The ribozymes showed specific
inhibition of HEV 3 end fused-luciferase reporter gene expression by 37 and 60%, respectively in HepG2 cells. These results
demonstrate a feasible approach to inhibit the HEV replication to a limited extent by targeting the cis-acting 3 end of HEV with
hammerhead ribozymes.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Hepatitis E virus (HEV) is the major causative agent for
feco-orally transmitted epidemic and sporadic acute viral
hepatitis in many developing countries (Purcell and Tice-
hurst, 1988; Bradely, 1990). The HEV genome is a positive-
sense, capped, and polyadenylated RNA of around 7.2 kb in
length, containing three open reading frames (ORFs) (Purdy
et al., 1993; Panda and Jameel, 1997; Kabrane et al., 1999;
Tyagi et al., 2002). The coding sequence in the HEV ge-
nome is flanked by 5 and 3 noncoding regions (NCRs) that
are 27 and 68 nucleotides long (Kabrane et al., 1999). It has
been demonstrated that the 3 noncoding region of HEV
forms stem–loop structures that contain cis-acting elements
which interact with viral RNA-dependent RNA polymerase
(RdRp) and cellular proteins required for virus replication
(Song and Simon, 1995; Agrawal et al., 2001). The inhibi-
tion of this interaction can block the viral replication. We
attempted to achieve the same by using designed ribozymes.
Ribozymes are RNA molecules that catalyze cleavage of a
target RNA molecule based on sequence-specific recogni-
tion (Uhlenbeck, 1987) and may have potential therapeutic
applications (James and Shamhkani, 1995). Ribozymes
have been previously used to inhibit gene expression in
viruses like HIV, HBV, and HCV and also neoplastic cells
(Dahm and Uhlenbeck, 1991; Chen et al., 1992; Parthasar-
athy et al., 1999; Macejak et al., 2000). This report demon-
strates in vitro and intracellular cleavage of HEV RNA
covering the RdRp binding domain by designed ribozymes.
Results
In vitro cleavage of HEV 3 end RNA by ribozymes
The hammerhead ribozymes were designed to cleave
HEV 3 end RNA in the stem–loop 2 region. Two target
sites, GUA and GUU at nucleotide (nt) positions 7112 and
7125, were selected from published secondary structure of
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HEV 3 end RNA (Agrawal et al., 2001). Mono-hammer-
head ribozyme was designed against the target site GUU
(7125), as shown in Fig. 1A. A Di-hammerhead ribozyme
was designed against two target sites GUA (7112) and GUU
(7125), as shown in Fig. 1B. The sense and antisense ri-
bozyme oligonucleotides were synthesized, annealed, and
cloned in the plasmid vector pcDNA3 (Invitrogen, The
Netherlands). Two ribozyme controls, one that is catalyti-
cally inactive due to a point mutation G5 to A in the
catalytic motif and the other with scrambled binding arms,
were also synthesized and cloned. Sequences of all the
ribozyme clones were confirmed.
Activities of the designed ribozymes were tested in vitro,
using target RNA and ribozyme RNA transcribed by T7
RNA polymerase from their respective plasmid vectors after
linearization at the 3 end of the construct. The transcript
sizes were 77 nt for the Di-Rz 7112/7125 and 44 nt for the
Mono-Rz 7125, respectively (Fig. 3A, lanes 1 and 5). The
transcript size of HEV 3 end target RNA was 115 nt (Fig.
3A, lane 3), which was obtained from the plasmid pUC18-
Fig. 1. Design of ribozymes and structures of ribozyme expression vectors. (A) Specific hybridization of Mono-Rz 7125 with target RNA at site GUU (7125).
Cleavage after U is indicated by arrow. (B) Specific hybridization of Di-Rz 7112/7125 with target RNA at target sites GUA (7112) and GUU (7125).
Cleavages after A and U are indicated by arrows. Inactive control Rz with point mutation in catalytic motif G53A is also shown. (C) Structure of ribozyme
expression vector, showing in vitro transcribed Rz RNA from T7 promoter and in vivo transcribed Rz RNA from CMV promoter by dashed arrows. (D)
Structure of ribozyme-fused firefly luciferase reporter vector. (E) Structure of ribozyme-fused EGFP reporter vector.
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HEV 3 end 7084–7194 (Fig. 2A and I). The cleavage
reactions were carried out with the [-33P]UTP-labeled
HEV 3 end RNA and unlabeled Rz (heat denatured) in
equimolar amounts (0.27 pmol each) under the standard
cleavage conditions (50 mM Tris–HCl, pH 7.5, 10 mM
MgCl2) and incubated at 37°C for 2 h. Di-Rz 7112/7125
cleaved the HEV 3 end substrate RNA into 74, 41, 28, and
13 nt fragments (Fig. 3A, lane 2), whereas Mono-Rz 7125
cleaved the substrate RNA into 74- and 41-nt fragments
(Fig. 3A, lane 4). The control-disabled ribozymes showed
no cleavage (Fig. 3C, lanes 1–4), indicating that the cleaved
products obtained were due to active ribozymes. The Di-Rz
7112/7125 and Mono-Rz 7125 cleaved up to 90 and 40% of
the target RNA. The cleavage efficiency of both the ri-
bozymes were tested at physiologically relevant concentra-
tions of MgCl2 (1–2 mM) and significant cleavages were
achieved by Di-Rz 38% (Fig. 3D, lanes 3 and 4) and by
Mono-Rz 10% (Fig. 3E, lanes 3 and 4). No cleavage was
observed in the absence of MgCl2 (Fig. 3D and E, lane 2).
Both the ribozymes cleave HEV 3 end RNA in a sequence-
specific manner that is protein-independent (Dahm and
Uhlenbeck, 1991; Santoro and Joyce, 1997). The bands
were quantified using a Bio-Rad GS-525 molecular imager
(Bio-Rad Laboratories, USA). Using similar experimental
conditions, cleavage efficiency of both the ribozymes were
tested against longer HEV 3 end transcript of 635 nt in
length transcribed from the plasmid pGEM-T Easy HEV 3
end 6616-7194 (Fig. 2A, II and Fig. 3B, lane 1). The
cleaved products were observed as expected (Fig. 3B, lanes
2–5) and cleavage was also obtained without heat denatur-
ation (90°C, 2 min) of the transcript (Fig. 3B, lanes 4 and 5),
indicating that both the ribozymes could access the target
site even when the native secondary folding of the RNA is
maintained. The cleavage rate was determined by taking
varying amounts of labeled HEV 3 end substrate RNA
under ribozyme saturating conditions. The Km and the Kcat
for the Di-Rz were 2.5  1013 M and 4.76  105 min1,
respectively, and for the Mono-Rz 5.5  1013 M and 1.2
 105 min1, respectively. The kinetic parameters suggest
that the Di-Rz 7112/7125 was more efficient of the two.
Intracellular expression of ribozymes
To determine the intracellular expression of ribozymes,
slot-blot hybridization analysis of the total cellular RNA
from cells transfected with the ribozyme expression vector
pcDNA3 Rz was used (Fig. 1C). Radiodensitometry analy-
sis showed that active and inactive ribozyme RNA were
expressed at about equal levels from transfected cells (Fig.
4A). Total cellular RNA was hybridized with radiolabeled
antisense Di-Rz probe in slots 2a (Di-Rz) and 2b (Di-Rz
mut) and antisense Mono-Rz probe in slots 2c (Mono-Rz)
Fig. 2. Structures of HEV 3 end and HEV 3 end-fused Luciferase containing vectors. (A) Structure of HEV 3 end vectors used for in vitro assays showing
template RNA transcripts made from T7 promoter of lengths 115 nt (I) and 635 nt (II) by dashed arrows. (B) Structure of HEV 3 end fused Luciferase vector
pSGI-HEV 3 end-Luc (I) and vector pSGI-Luc lacking HEV 3 end (II) used for in vivo assays. SV40 early promoter initiated intracellular expression from
these vectors.
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and 2d (Mono-Rz mut) to detect the sense Rz RNA. Slots
1a, 1b, 1c, and 1d show that none of the probes hybridize
with RNA from untransfected control cells (Feng et al.,
2001). The intracellular expression of ribozymes was fur-
ther confirmed by ribozyme-fused reporter gene vectors
pcDNA3 Rz-Luc (firefly luciferase) (Fig. 1D) and pcDNA3
Rz-EGFP (enhanced green fluorescent protein) (Fig. 1E) in
transient transfection assay in HepG2 cells. Reporter gene
expression levels were found to increase with increasing
concentrations of the vector DNA (Fig. 4B and C).
Intracellular cleavage of HEV 3 end RNA by ribozymes
The activity of endogenously expressed ribozymes were
tested in HepG2 cells by use of a target–reporter vector
pSGI-HEV 3 end–Luc generated by fusing HEV 3 end and
firefly luciferase (Luc) gene under the control of SV40 early
promoter (Fig. 2B, I). The effects of the ribozymes were
analyzed by cotransfection experiments using equal concen-
trations (1 g each) of the ribozyme and reporter target
vector followed by luciferase assay. Plasmid pRL-SV40
(Promega, USA) carrying Renilla luciferase (R-Luc) gene
served as an internal control. The reduction of luciferase
activity by60% (Di-Rz 7112/7125) and37% (Mono-Rz
7125) respectively (Fig. 5A) was observed. The catalyti-
cally inactive ribozymes (Rz mut) also down-regulated the
luciferase expression in this system. However, the extent of
this inhibition (37% by Di-Rz 7112/7125 mut and 22%
by Mono-Rz 7125 mut, Fig. 5A) was much less than that
produced by the active ribozymes. This inhibitory effect
was likely to be from an antisense effect that destabilises the
mRNA by base pairing. This was further substantiated by
Fig. 3. In vitro cleavage analyses of HEV 3 end RNA by ribozymes. (A) Cleavage of HEV 3 end RNA of length 115 nt, lane 1 and 5 shows sizes of Di-Rz
7112/7125 (77 nt) and Mono-Rz 7125 (44 nt). Uncleaved HEV 3 end RNA transcript of length 115 nt is shown in lane 3. Cleavage of HEV 3 end RNA
into cleaved products 74, 41, 28, and 13 nts by Di-Rz 7112/7125 (lane 2) and by Mono-Rz 7125 into cleaved products 74 and 41 nts (lane 4). (B) Cleavage
of HEV 3 end longer transcript of length 635 nt. Lane 1 shows uncleaved target RNA. Lane 2 and 3 shows cleavage by Di-Rz 7112/7125 and Mono-Rz
7125 along with cleaved products. Efficient cleavage of target RNA by Di-Rz 7112/7125 (lane 4) and Mono-Rz 7125 (lane 5) was also observed without
heat denaturation step (90°C for 2 min.). (C) Cleavage with catalytically inactive ribozymes. (Lane 1) Di-Rz (mut), (lane 2) Di-Rz (dis), (lane 3) Mono-Rz
(mut), and (lane 4) Mono-Rz (dis). All the lanes show no cleaved products of the target RNA. (D) and (E) Cleavage at physiological MgCl2 concentration.
Lanes 3 and 4 of (D) and (E) show cleavage at 1 and 2 mM of MgCl2 of Di-Rz and Mono-Rz respectively. No cleavage without MgCl2 in lane 2 and lane
1 shows only substrate transcript of length 115 nt.
353B. Sriram et al. / Virology 312 (2003) 350–358
Fig. 4. Intracelluar expression of anti-HEV ribozymes. (A) Ribozyme expression of plasmids pcDNA3 Di-Rz/Mono-Rz in transfected HepG2 cells was
verified by using slot-blot analysis of total cellular RNA. Thirty micrograms of total cellular RNA were hybridized with radiolabeled ribozyme antisense
probe Di-Rz in lanes 2a (Di-Rz) and 2b (Di-Rz mut) and antisense Mono-Rz probe in lanes 2c (Mono-Rz) and 2d (Mono-Rz mut). Lanes 1a, 1b, 1c, and
1d show no hybridization since the RNA blotted was from untransfected cells. (B) One and 2 g of ribozyme-fused firefly luciferase reporter vector pcDNA3
Rz-Luc were transfected and assayed for luciferase assay. Luciferase expression levels were found to increase with increase in dose. (C) Two micrograms
of ribozyme-fused EGFP reporter vector pcDNA3 Rz-Luc were transfected and the green fluorescence was observed by confocal microscopy. Cells only and
parent vector pcDNA3 show no expression levels.
the observation that the disabled ribozymes (Rz dis) with
scrambled binding arms showed no inhibition in the lucif-
erase expression. pcDNA3 Rz X, a nonspecific ribozyme
directed against HIV-1 gag sequence, also failed to inhibit
luciferase expression (Fig. 5A).
Using infectious HEV clone pSGI-HEV [I] (Panda et al.,
2000), reduction in the HEV 3 end RNA by ribozymes was
detected by reverse transcription–polymerase chain reaction
(RT–PCR) and quantified by real-time PCR using the
SYBR-Green dye method. Lane 1 in Fig. 5B shows the
levels of HEV 3 end RNA when 1 g of pSGI-HEV [I]
plasmid alone was transiently expressed. Lanes 2 and 3
show the levels of RNA when cotransfected with 3 g of
pcDNA3 Mono-Rz and pcDNA3 Di-Rz, and lanes 4, 5, and
6 show those when cotransfected with 3 g of each Rz X,
disabled Di-Rz, and disabled Mono-Rz, respectively. The
RT–PCR controls, lane 7 (plain cells), lane 8 (without
reverse transcriptase enzyme), and lane 9 (without template)
showed no amplification. The human glyceraldehyde-3-
phosphate dehydrogenase (hGAPDH) was also amplified
from the equivalent amount of cell lysate that served as an
internal control (Weinberg et al., 2000). The hGAPDH
RNA levels observed after RT–PCR remained the same in
all corresponding lanes (Fig. 5C). Real-time RT-PCR assay
was used to measure quantitatively total levels of HEV 3
end RNA from the standard curve of HEV 3 end RNA
using SYBR-Green PCR mix (Yang et al., 2002). The quan-
tity of 3 end HEV RNA was reduced by 30% (2.2  108
copies of RNA) by Mono-Rz and around 50% (1.6  108
copies of RNA) by Di-Rz in comparison to the levels in the
cells transfected with pSGI-HEV [I] plasmid alone (3.4 
108 copies of RNA). From these observations it was de-
duced that the reduction was due to specific intracellular
cleavage by ribozymes in these experiments.
Discussion
This study was designed to determine the use of ham-
merhead ribozymes to specifically target HEV RNA at the
site of interaction with RdRp and to evaluate the efficacy of
these trans-acting Mono- and Di-ribozymes in cleavage of
HEV RNA in vitro and in HepG2 cells. Two target sites
GUA (7112) and GUU (7125) were selected (Fig. 1A and
B) on the basis of the confirmed secondary structure in the
single-stranded region of the HEV 3 end (Agrawal et al.,
2001). The advantage of Di-Rz or multi-target Rzs is to
increase the overall cleavage efficiency and to prevent the
development of escape mutants. Multi-target ribozymes
have been designed earlier by linking Mono-Rz against HIV
and were found to be more efficient than Mono-Rzs (Chen
et al., 1992). However, in those instances the target sites
were distantly apart. In this study, we report a Di-Rz against
two closely spaced target sites with an internal binding arm
along with 5 and 3 terminal binding arms (Fig. 1B) and
found that there was cleavage induced by the two motifs
simultaneously (Fig. 3A, lane 2). Di-Rz was found more
efficient in cleaving the substrate RNA under standard in
vitro conditions than Mono-Rz 7125. This could be due to
Fig. 5. Intracellular cleavage of HEV 3 end RNA by ribozymes. (A)
Cotransfection of pcDNA3 Rz and pSGI-HEV 3 end-Luc plasmids. Both
Mono-Rz and Di-Rz interfered very efficiently in luciferase expression.
Inhibition of luciferase expression was also found in the case of mutant
ribozymes (Rz mut). Disabled ribozymes (Rz dis) at equivalent concen-
trations had no effect on the levels of luciferase activity. The extent of
luciferase activity detected by cotransfecting 1 g of pSGI-HEV 3 end-
Luc and 1 g of unrelated pcDNA3 Rz X was taken as 100%. Renilla
luciferase activity was detected to normalize the variation of transfection
efficiency among different samples. Shown are the mean  SD from three
separate experiments. (B) Reduction in HEV 3 end RNA by ribozymes
detected by RT–PCR. (Lane 1) The amount of HEV 3 end RNA detected
from cells transfected only with pSGI-HEV [I] plasmid (1 g). When
cotransfected with 3 g of each Mono-Rz (lane 2) and Di-Rz (lane 3)
plasmids, reduced expression was found that was quantitated by real-time
PCR from the standard curve plotted using SYBR-Green PCR master mix.
Rz X, disabled Mono-, and Di-Rzs (lanes 4, 5, and 6) showed no reduction
in the levels of target RNA. RT–PCR controls in lane 7 (cells only), lane
8 (without reverse transcriptase enzyme), and lane 9 (without template)
showed no amplification. (C) The same amounts of lysates were used as in
B and levels of the control RNA was determined for the hGAPDH gene
using its specific terminal primers. The levels of control RNA in all
corresponding lysates remained unchanged.
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the ability of Di-Rz to cleave substrate into multiple RNA
fragments and increased turnover of the cleavage reaction as
previously reported (Chen et al., 1992). We also found that
both the ribozymes were equally efficient in cleaving the
longer HEV transcript of 635 nt under standard in vitro
cleavage conditions (Fig. 3B), which confirms the accessi-
bility of the ribozymes to the target sites and sequence
specificity of the cleavage. The important feature of both
Rzs was their ability to cleave the target RNA at MgCl2
concentrations of 1 and 2 mM (Fig. 3D and E, lanes 3 and
4), which are close to the physiological levels (Santoro and
Joyce, 1997). The kinetic parameters of both the Rzs were
found to be equally efficient when compared with the other
Rzs and DNA enzymes that have been reported (Santoro
and Joyce, 1997). This high efficiency could be due to the
fact that the Rz RNA had no substantial proportions of
vector sequences that could affect secondary structure of
ribozymes, substrate binding, and cleavage steps.
Slot-blot hybridization and ribozyme-fused reporter gene
assays confirmed the endogenous expression of anti-HEV
ribozymes (Fig. 4A–C). Since there is no cell culture system
available for HEV to evaluate the efficacy of these anti-
HEV Rzs, target–reporter vector pSGI-HEV 3 end–Luc
(Fig. 2B) was used to demonstrate intracellular cleavage of
HEV 3 end RNA. Any cleavage in HEV 3 end RNA
would result in down-regulation of luciferase expression.
Similar constructs have been used to evaluate Rzs and DNA
enzymes against hepatitis C virus (HCV) (Sakamoto et al.,
1996) and hepatitis B virus (HBV) (Macejak et al., 2000).
Around 60% and 37% of inhibition in luciferase expression
were found when Di-Rz and Mono-Rz plasmids were co-
transfected with vector containing HEV 3 end–Luc (Fig.
5A). This reduction in luciferase expression by anti-HEV
ribozymes was comparable with other ribozymes (Saka-
moto et al., 1996; Macejak et al., 2000). It is evident that
whatever reduction in luciferase expression was observed
was due to intracellular cleavage of HEV 3 end RNA by
active ribozymes (Sakamoto et al., 1996). We also observed
reduction in luciferase expression levels by catalytically
inactive point mutated ribozymes (Di-Rz 7112/7125 mut
37%; Mono-Rz 7125 mut22%) (Fig. 5A). These mutant
Rzs do not cleave its target RNA but still reduces gene
expression, presumably due to an antisense effect. The
higher inhibition by active ribozymes indicates that the
active catalytic domain of the hammerhead ribozyme could
increase the extent of inhibition on top of the antisense
inhibition (Feng et al., 2001). This is not unexpected since
the formation of helices I and III (Fig. 1A and B) is a
prerequisite for mediating hydrolytic cleavage and poten-
tially gives rise to an antisense effect (Feng et al., 2001).
However, there are reports that the inhibition was more
pronounced with the active ribozyme than with catalytically
inactive one when applied exogenously (Bramlage et al.,
1999). There was no reduction in luciferase expression by
disabled Rzs with scrambled arms and with unrelated Rz X
(Fig. 5A), which lacks the ability to hybridize to the sub-
strate RNA. Therefore, the suppression of luciferase activity
in the present study suggests that anti-HEV Rzs could ac-
cess the target sites and cleave HEV 3 end RNA intracel-
lularly. The reduction in the HEV 3 end RNA levels was
demonstrated by RT–PCR and quantitative real-time PCR
from cotransfection experiments of anti-HEV Rzs with the
infectious HEV clone pSGI-HEV [I]. The reduction in the
HEV 3 end RNA levels by Mono-Rz (30%) and Di-Rz
(50%) (Fig. 5B, lanes 2 and 3) were compared with the
levels of the RT–PCR product of the HEV 3 end (Fig. 5B,
lane 1). As expected, unrelated Rz X and disabled ri-
bozymes did not show any reduction in the target RNA
levels (Fig. 5B, lanes 4–6). The corresponding lysates
showed almost no reduction in the levels of the housekeep-
ing RNA (hGAPDH) used as an internal control (Fig. 5C).
Thus we conclude that anti-HEV Rzs cleave specifically
HEV 3 end RNA, which is generated from infectious HEV
clone pSGI-HEV [I] in the transfected cells.
In summary, this report describes the efficacy of Mono-
and Di-Rzs designed to cleave target HEV RNA both in
vitro and in HepG2 cells. The potential therapeutic impli-
cation of such ribozymes in self-limiting infection to pre-
vent development of liver failure needs to be investigated.
Materials and methods
Construction of ribozyme expression vector
Both sense and the complementary oligonucleotide se-
quences encoding ribozymes were synthesized on an auto-
mated DNA synthesizer (Model 392, Applied Biosystems,
USA). Cleavage-deficient ribozymes, one with a G5 3 A
point mutation (Rz mut) in the catalytic domain of the
hammerhead ribozyme (Fig. 1A and B), which allows bind-
ing to the target RNA but lacks the cleavage ability, and
another with scrambled flanking sequences in the binding
arms, which totally lacks binding capability to the target
RNA (Rz dis), were also synthesized for control experi-
ments. As an additional negative control, a known ribozyme
(pcDNA3 Rz X), which was directed against gag region of
HIV genome, was used for checking specificity of the de-
signed anti-HEV ribozymes (this plasmid was a gift from
Dr. Akhil C Banerjea, National Institute of Immunology,
New Delhi, India). The oligonucleotides with 5 HindIII and
3 BamHI cohesive ends (added during synthesis) were
phosphorylated, annealed, and cloned into the equivalent
restriction sites of the vector pcDNA3 (Invitrogen, The
Netherlands). The plasmids were named as pcDNA3 Rz
7125 and pcDNA3 Rz 7112/7125.
Construction of ribozyme-fused reporter gene vectors
Reporter genes, firefly luciferase (Luc) and enhanced
green fluorescent protein (EGFP), were fused with anti-
HEV ribozyme gene individually to determine the intracel-
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lular expression of ribozymes quantitatively and qualita-
tively. Reporter gene firefly luciferase was cloned at BamHI
site of vector pcDNA3 Rz giving rise to recombinant vector
pcDNA3 Rz-Luc (Fig. 1D). Similarly, reporter gene EGFP
was cloned at BamHI and NotI sites of vector pcDNA3 Rz
to give rise to recombinant vector pcDNA3 Rz-EGFP (Fig.
1E). Both the ribozyme-fused reporter gene constructs were
confirmed by restriction digestion and sequencing.
Construction of HEV 3 end target vectors
Two kinds of HEV substrate constructs were used for in
vitro cleavage reaction: plasmid pUC18 HEV nt 7084–7194
(Fig. 2A, I), which was recently reported by us (Agrawal et
al., 2001) as RdRp-binding region, and plasmid pGEM-T
Easy nt 6616–7194 (Fig. 2A, II). DNA encoding the 3 end
of HEV was amplified by their specific terminal primers
using HEV cDNA nt 6046–7194 pPCR-Script clone re-
ported by us (Panda et al., 1995).
Construction of HEV–luciferase reporter gene expression
vector
Infectious HEV cDNA clone pSGI-HEV [I] (AF076239)
reported by us (Panda et al., 2000) was digested by SacI and
XhoI to release HEV 3 end, 7086–7194 nt, and cloned into
the equivalent restriction sites of pSGI (construct: pSGI-
HEV 3 end). Firefly luciferase reporter gene was cloned
into the pSGI-HEV 3 end at the BamHI site (construct:
pSGI-HEV 3 end-Luc) (Fig. 2B, I). As a control, plasmid
pSGI-Luc that lacks the HEV 3 end was constructed (Fig.
2B, II). In both the constructs, expression of the genes was
driven by SV40 early promoter and also by T7 promoter.
In vitro transcription and in vitro cleavage reaction
Ribozyme expression plasmids pcDNA3 Rz 7125 and
pcDNA3 Rz 7112/7125 were linearized with BamHI and
transcribed in vitro by T7 RNA polymerase. The substrate
HEV 3 end RNA plasmids pUC18-HEV 7084–7194 were
linearized with XhoI and transcribed by T7 RNA polymer-
ase in the presence of -[33P]UTP and RNA products were
treated with RQI DNAse according to the supplier’s recom-
mendations (Promega, USA). For in vitro cleavage reaction,
equimolar concentrations (0.27 pmol each) of the
-[33P]UTP-labeled substrate RNA and unlabeled ri-
bozymes were preincubated at 90°C for 2 min and then
mixed under standard cleavage conditions (50 mM Tris–
HCl, pH 7.5, 10 mM MgCl2) in 10 l of reaction volume
and incubated at 37°C for 2 h. The reactions were termi-
nated by adding formamide-loading buffer with EDTA. The
products of the cleavage reactions were resolved by elec-
trophoresis on an 8% polyacrylamide/7 M urea gel. The
cleaved RNA bands were detected by autoradiography of
the dried gels. The cleaved RNA fragments were quantified
with the help of a Bio-Rad GS-525 molecular imager (Bio-
Rad Laboratories, USA).
Cell culture and transfection
Human hepatoma cell line (HepG2), was maintained in
Dulbecco’s modified Eagle’s medium (Life Technologies,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (Life Technologies, USA), 10 g/ml streptomycin,
and 100 U/ml penicillin (Sigma, USA). For transfection,
exponentially growing HepG2 cells were seeded onto
30-mm tissue culture petriplates at a density of 2 105 cells
per plate and incubated overnight (at least 18 h) to yield
50–70% confluency on the day of transfection. Cationic-
lipid-mediated (Lipofectamine Plus Reagent, Life Technol-
ogies, USA) transfection was carried out in accordance with
the manufacturer’s guidelines with a combination of 1 g of
target plasmids (pSGI-HEV 3 end-Luc/pSGI-HEV [I]) and
1–3 g of ribozyme plasmids (pcDNA3 Rz 7125 and
pcDNA3 Rz 7112/7125). 0.5 g of plasmid pRL-SV40
(Promega, USA) containing Renilla luciferase gene (R-Luc)
was cotransfected as an internal control. Luciferase activity
was determined 48 h after cotransfection with a Dual-Lu-
ciferase Reporter Assay (Promega, USA) according to the
manufacturer’s instructions. R-Luc activity was detected to
normalize the variation of transfection efficiency among
different samples. All the experiments were repeated at least
thrice and results reported were reproducible and expressed
as the mean  SD in relative light units RLU/mg protein or
as percentage of activity. Light emission was measured by
TD 20/20 Luminometer (Promega, USA).
Total RNA extraction and slot-blot analysis
Two days after transfection, cells were harvested and
lyzed in Trizol solution (Life Technologies, USA), and total
RNA was isolated by chloroform extraction and isopropanol
precipitation. The slot-blot analysis was carried out by stan-
dard method (Maniatis et al., 1989). Thirty micrograms of
total RNA was immobilized onto a Hybond-N nylon mem-
brane (Amersham Pharmacia Biotech, UK) by gentle suc-
tion with a blotting manifold (Life Technologies, USA).
Hybridization was carried out by adding -[33P]UTP
(BRIT, INDIA) labeled in vitro transcribed antisense ri-
bozyme RNA (Di-Rz and Mono-Rz) and incubating the
membrane at 42°C overnight. The relative ribozyme expres-
sion levels were determined by using radiodensitometry.
RT–PCR detection of HEV 3 end RNA
Equal amounts of RNA (1 g) were taken and subjected
to RT–PCR using the cyclic conditions and HEV 3 end-
specific terminal primers as described earlier (Agrawal et
al., 2001). The control RNA (587 bp), human glyceralde-
hyde-3-phosphate dehydrogenase (hGAPDH) was amplified
from its specific terminal primers (Weinberg et al., 2000). A
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standard curve of HEV 3 end RNA was made from a
10-fold serial dilution of the in vitro transcribed HEV 3 end
RNA from the linearized plasmid pUC18-HEV 3 end
7084–7194 was reverse transcribed by gene-specific reverse
primer with 100 U of MMLV reverse transcriptase enzyme
(Life Technologies, USA) into cDNA, which was then am-
plified by real-time PCR using SYBR-Green PCR mix
(ABI, USA) with the specific primers of HEV 3 end (Yang
et al., 2002). The Perkin–Elmer ABI Prism 7700 Sequence
Detection System was used for real-time analysis.
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